Chromosomal Crossover News and Research

RSS

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2012

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.

24 May 2012

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.

23 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer Inc. announced the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu.

19 May 2012

DCI receives FDA approval for PERTZYE NDA to treat EPI

Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.

19 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

No significant differences in absorption between tablet and softgel capsule forms of folic acid

The bioavailability of folic acid does not significantly differ between delivery in standard tablet or softgel capsule forms, according to research published in this month's Journal of the Academy of Nutrition and Dietetics. Folic Acid helps support a women's pregnancy and development of a healthy newborn.

17 May 2012

Eggs for breakfast associated with greater satiety and reduced calorie consumption

New research presented at the 19th European Congress on Obesity in Lyon, France reports that eating eggs for breakfast is associated with greater satiety and reduced calorie consumption at lunch than eating wheat-based breakfast foods like ready-to-eat breakfast cereal. Participants in the study reported feeling fuller following the egg breakfast and tests of their hunger hormone levels supported their self-reported observations.

14 May 2012

Lenalidomide improves overall survival for patients with multiple myeloma

Data from the first large U.S. study assessing the effectiveness of long-term "maintenance" therapy with lenalidomide for patients with multiple myeloma show that the drug significantly improves the time to progression and overall survival for patients with this often-deadly hematologic cancer.

10 May 2012

CAPE arrests growth of prostate cancer cells and tumors in mice

An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine.

4 May 2012

JLGTD to publish results from Cutaneous Lysate study on vulvodynia

The results from Dr. Gilbert G. Donders' MD, PhD study testing Cutaneous Lysate in women suffering from vulvar pain has been accepted for publication in the Journal of Lower Genital Tract Disease.

2 May 2012

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine.

26 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Study points to positive health benefits of fibers

For years, fiber intake among the global population has been extremely low, setting the stage for potentially serious, long-term public health implications. New research commissioned by Tate & Lyle and presented at the 2012 Experimental Biology conference in San Diego adds to the body of emerging research on fibers, including additional support for the role of soluble corn fiber in bone health.

24 Apr 2012

Missing tool helps sperm and eggs develop exactly 23 chromosomes each

Researchers at the University of California, Davis have discovered a key tool that helps sperm and eggs develop exactly 23 chromosomes each. The work, which could lead to insights into fertility, spontaneous miscarriages, cancer and developmental disorders, is published April 13 in the journal Cell.

16 Apr 2012

Positive top-line results from Biodel’s Phase 1 trial of two RHI-based formulations

Biodel Inc. today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin.

16 Apr 2012

QRxPharma completes MoxDuo CR Phase 1 studies on chronic pain

QRxPharma announced today successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.

11 Apr 2012

A step closer to correcting unhealthy gene mutations with diet

Scientists have moved a step closer to correcting some unhealthy gene mutations with diet, according to a new research report appearing in the April 2012 issue of the journal GENETICS.

9 Apr 2012

Bioness commences StimRouter Neuromodulation System study for chronic peripheral nerve pain

Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.